The dispersible tablet is not approved for local use.

Treatment has limited use in practice - it is second line treatment only utilised if patients are intolerant to alendronic acid therapy

Specialist initiation

Reduction of bone damage in bone metastases in breast cancer

Ipswich Hospital

Ibandronic acid injection is a formulary medicine - for postmenopausal osteoporosis for patients unable to take/intolerant to oral medicines

Colchester Hospital

Ibandronate acid injection is considered non-formulary

Specialist initiated

Bone pain only

Note 2 different strengths of Zolendronic acid

For oncology related indications

Note 2 different strengths of Zolendronic acid

 For osteoporosis and Paget's disease

MHRA:Osteonecrosis of the external auditory canal

MHRA: Osteonecrosis of the jaw

Note two different brands

Prolia is indicated for 

• Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures
• Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures

For osteoporosis-NICE TA204

Ipswich Hospital/IESCCG

Denosumab (for osteoporosis) is considered a "hospital-only" medicine

Colchester Hospital/NEECCG

Denosumab (for osteoporosis) is available for Primary Care prescribing under a Shared Care Agreement

MHRA:Osteonecrosis of the external auditory canal

MHRA: Osteonecrosis of the jaw

MHRA:Denosumab (Xgeva▼) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation

MHRA:Denosumab (Xgeva▼) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronate

Note two different brands

XGEVA is indicated for 

• Prevention of skeletal related events in patients with bone metastases from solid tumours